Scientists, Engineers, and Leaders Who Participated Directly in the Report, Or Who Became Aware of the Report and Asked to Sign

Total Page:16

File Type:pdf, Size:1020Kb

Scientists, Engineers, and Leaders Who Participated Directly in the Report, Or Who Became Aware of the Report and Asked to Sign Scientists, engineers, and leaders who participated directly in the report, or who became aware of the report and asked to sign the letter “Convergence: The Future of Health.” Fred Abernathy Harvard University American Institute of Biological Sciences Ariel Amir Harvard University Kristi Anseth University of Colorado at Boulder Amanda Arnold Square Set Strategies Frances Arnold California Institute of Technology Sylvia L. Asa University Health Network, University of Toronto Dennis A. Ausiello Massachusetts General Hospital Jose L. Avalos Princeton University Demba Ba Harvard University Vikram Bajaj GRAIL and Verily (Google Life Sciences) Sangeeta Bhatia Massachusetts Institute of Technology Steven Block Stanford University Roger Brockett Harvard University John L. Brooks III Healthcare Capital Emery N. Brown Massachusetts Institute of Technology, Massachusetts General Hospital, Harvard Medical School John E. Burris Burroughs Wellcome Fund Andrea Califano Columbia University Arup K. Chakraborty Massachusetts Institute of Technology Jennifer Chayes Microsoft Research Steven Chu Stanford University Miyoung Chun The Kavli Foundation Todd Coleman University of California at San Diego James J. Collins Massachusetts Institute of Technology, Broad Institute of MIT and Harvard, Wyss Institute, Harvard University Joseph DeSimone University of North Carolina at Chapel Hill, North Carolina State University, Carbon Inc. Robert Desimone Massachusetts Institute of Technology James DiCarlo Massachusetts Institute of Technology John Donoghue Brown University Finale Doshi-Velez Harvard University Frank Doyle Harvard University Sean R. Eddy Howard Hughes Medical Institute, Harvard University Andrew Ewald Johns Hopkins University Gabriele Fariello Harvard University Brian Farrell Harvard University Martin Fussenegger ETH Zurich Krzysztof Gajos Harvard University Sharon Gillett Microsoft Research Roy Gordon Harvard University Jeff Gore Massachusetts Institute of Technology Robert C. Green Brigham & Women's Hospital, Broad Institute, Harvard Medical School Melvin Greer Intel Corporation Barbara J. Grosz Harvard University Taekjip Ha Johns Hopkins University Paula Hammond Massachusetts Institute of Technology Jim Heath California Institute of Technology Yu-Chi Ho Harvard University Susan Hockfield Massachusetts Institute of Technology Evelyn Hu Harvard University Darrell J. Irvine Massachusetts Institute of Technology Tyler Jacks Massachusetts Institute of Technology Neel Joshi Harvard University Alexander V. Kabanov University of North Carolina at Chapel Hill Russell Kelley Burroughs Wellcome Fund Peter S. Kim Stanford University Charlotte Kuperwasser Tufts University Robert Langer Massachusetts Institute of Technology Cato T. Laurencin University of Connecticut Herbert Levine Rice University Jennifer A. Lewis Harvard University Bruce T. Liang University of Connecticut School of Medicine J. Christopher Love Massachusetts Institute of Technology Timothy Lu Massachusetts Institute of Technology L Mahadevan Harvard University Susan Marqusee University of California at Berkeley Eric Mazur Harvard University Ari Melnick Weill Cornell Medical College Yasmine Meroz Harvard University Chad A. Mirkin Northwestern University Michael Mitchell Massachusetts Institute of Technology Anthony Monaco Tufts University David Mooney Harvard University Linsey Moyer Harvard University Amir Nashat Polaris Partners David R. Nelson Harvard University Robert M. Nerem Georgia Institute of Technology Joel Oppenheim New York University School of Medicine Nicholas A. Peppas The University of Texas at Austin Peter Pershan Harvard University Roderic Pettigrew Tomaso Poggio Massachusetts Institute of Technology Stephen Quake Chan Zuckerberg Biohub, Stanford University Rebecca Richards-Kortum Rice University Peter Rogers Harvard University Sadasivan Shankar Harvard University Phillip A. Sharp Massachusetts Institute of Technology Susan Rundell Singer Rollins College Maurice Smith Harvard University Michael D. Smith Harvard University Peter Szolovits Massachusetts Institute of Technology Laura H. Tang Memorial Sloan Kettering Cancer Center Henri Termeer Biotechnology Matthew Tirrell University of Chicago Mehmet Toner Massachusetts General Hospital, Harvard Medical School Leslie Valiant Harvard University Evan Vosburgh West Haven Veterans Administration Hospital, Yale University Jim Waldo Harvard University Tandy Warnow The University of Illinois at Urbana-Champaign Ralph Weissleder Harvard Medical School, Massachusetts General Hospital David Weitz Harvard University Phyllis M. Wise University of Illinois at Urbana-Champaign Owen Witte University of California at Los Angeles Peter Guy Wolynes Rice University Tai Tsun Wu Harvard University Wyss Institute for Biologically Inspired Engineering at Harvard University Xiaoliang Sunney Xie Harvard University Raymond Yeung University of Washington Michael W. Young The Rockefeller University Xiaowei Zhuang Harvard University, Howard Hughes Medical Institute Maria T. Zuber Massachusetts Institute of Technology .
Recommended publications
  • Boston University Journal of Science & Technology
    4 B.U. J. SCI. & TECH. L. 1 January 23, 1997 Boston University Journal of Science & Technology Law Symposium Financing the Biotech Industry: Can the Risks Be Reduced? Ronald Cass, Joshua Lerner, Farah H. Champsi, Stanley C. Erck, Jonathan R. Beckwith, Leslie E. Davis, Henri A. Termeer Table of Contents Speeches..........................................................................................................................[1] Dean Ronald Cass.............................................................................................[1] Joshua Lerner....................................................................................................[2] Farah Champsi..................................................................................................[8] Stanley Erck.....................................................................................................[18] Jonathan Beckwith.........................................................................................[24] Leslie Davis......................................................................................................[37] Henri Termeer.................................................................................................[47] Question and Answer Session..................................................................................[60] Financing the Biotech Industry: Can the Risks Be Reduced?† Jonathan R. Beckwith, Farah H. Champsi, Leslie E. Davis,* Stanley C. Erck, Joshua Lerner, Henri A. Termeer Dean Ronald Cass: 1. The biotechnology
    [Show full text]
  • Schedule 14A
    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • AVEO PHARMACEUTICALS, INC. (Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 AVEO PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials: ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Proqr Therapeutics N.V
    ANNUAL REPORT 2017 Meaningful progress - Excited about the future PAGE I PAGE II ANNUAL MAGAZINE 2017 ANNUAL MAGAZINE 2017 our courage to do things differently University of Colorado and during his ACCOMPLISHMENTS – and challenge the status quo. career has earned a global reputation A QUICK GLANCE We can and will make a meaningful for translating cutting-edge science impact – changing the lives of into transformational new therapies Eluforsen (formely known as QR-010) for CF patients. Be it in a small way – for rare diseases including cystic fibro- • Completed second trial for eluforsen by improving one’s quality of life. sis, pulmonary fibrosis, pulmonary • Announced positive data from Or in a big way – by stopping artery hypertension, severe immuno- Phase 1b safety and tolerability study a disease or by curing patients. logic, and inflammatory diseases. • Received FDA Fast Track designation and Orphan Drug Designation (ODD) CREATING MEANINGFUL IMPACT At ProQR, we do it all in the interest Dave is excited to be part of ProQR’s in US and Europe of patients. We’re driven, deter- management team: “ProQR has • Granted two key patents mined, excited to make this differ- a patient-centric culture committed ence. Today, tomorrow and more to transforming lives. Applying our QR-110 for LCA 10 days to come, until we get it right. RNA editing platform to precision • IND clearance from FDA and IN THE INTEREST medicine in hereditary forms of commenced Phase 1/2 safety and Building ProQR blindness, dystrophic epidermolysis efficacy trial In 2017, we made important strides bullosa, cystic fibrosis and other • First patient in trial dosed in late 2017 in ProQR’s growth.
    [Show full text]
  • Orphan Drug Letters
    November 18, 2010 Kent Lieginger Senior Vice President, Managed Care and Customer Operations Genentech 1 DNA Way South San Franciso, CA 94080 Dear Dr. Lieginger: We are writing on behalf of a broad coalition of hospitals participating in the federal 340B drug discount program. We have been advised that Genentech has begun to withhold 340B pricing for orphan drugs purchased by a subset of our membership, primarily children’s and rural hospitals. We are aware that, under the Health Care and Education Reconciliation Act (HCERA), Congress established a statutory exclusion with respect to orphan drugs purchased by hospitals specifically added by the Patient Protection and Affordable Care Act (PPACA) to the 340B program under the Public Health Service Act, including freestanding cancer hospitals, children’s hospitals, sole community rural referral centers, and critical access hospitals. 1 However, we are deeply concerned with Genentech’s broad interpretation of the orphan drug exclusion, which Genentech has stated extends to all drugs that have been designated “orphan” by the FDA, regardless of the intended use of the drugs. We believe that, absent guidance from the Health Resources and Services Administration (HRSA) regarding the scope of the orphan drug exclusion, it is premature to withhold 340B pricing on orphan drugs. Accordingly, we request that Genentech resume its sale of orphan drugs to hospitals identified in PPACA at 340B prices until directed otherwise by HRSA. We understand that several manufacturers have decided to delay implementation until they receive further guidance from the government and ask that you follow their lead. Our concerns regarding your company’s interpretation are two-fold.
    [Show full text]
  • Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. As Recipient of BIO’S 2019 Henri A
    Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award May 29, 2019 NOVATO, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that the Biotechnology Innovation Organization (BIO) has awarded this year’s Henri A. Termeer Biotechnology Visionary Award to Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer, President and founder of Ultragenyx. The award, which will be presented to Dr. Kakkis on June 5 during the BIO 2019 International Convention keynote session, recognizes Dr. Kakkis’ transformative work to accelerate research and development of novel treatments for rare diseases. “Henri Termeer was a pioneer who worked relentlessly to do what many thought was impossible and bring therapies to patients with rare diseases,” said Dr. Kakkis. “I am deeply honored to receive this award from BIO.” “Dr. Kakkis’ innovative work has pushed the boundaries of our knowledge in rare diseases and through his efforts our industry better prioritizes treatments for rare and ultra-rare diseases and understands the unique needs of clinical trials in this category,” said Jim Greenwood, President and CEO of BIO. “His contributions to the study of rare diseases have been monumental for patients and families, and we’re looking forward to presenting him with this well-deserved honor at BIO 2019.” Over the last 25 years, Dr. Kakkis has spearheaded the development of many rare disease treatments, including an enzyme replacement therapy for the rare and debilitating disorder, mucopolysaccharidosis type I (MPS I), which was approved by the FDA in 2003.
    [Show full text]
  • Biotechnology Summit: Putting a Human Face on Biotechnology
    17Rla S. HRG. 106-677 BIOTECHNOLOGY SUMMIT: PUTTING A HUMAN FACE ON BIOTECHNOLOGY HEARING before the JOINT ECONOMIC COMMITTEE CONGRESS OF THE UNITED STATES ONE HUNDRED SIXTH CONGRESS FIRST SESSION September 29, 1999 PRINTED FOR THE USE OF THE JOINT ECONOMIC COMMITFEE U.S. GOVERNMENT PRINTING OFFICE WASHINGTON: 2000 CC 62-990 FOR SALE BY THE U.S. GOVERNMENT PRINTING OFFICE SUPERNTENDENTOF DOCUMEN CONGRESSIONALSALESOFFICEWASHINGTON, D.C20402 JOINT ECONOMIC COMMITTEE [Created pursuant to Sec. 5(a) of Public Law 304, 79th Congress] SENATE HOUSE OF REPRESENTATIVES CONNIE MACK, Florida, Chairman JIM SAXTON, New Jersey, Vice Chairman WILLIAM V. ROTH, JR., Delaware MARK SANFORD, South Carolina ROBERT F. BENNETT, Utah JOHN DOOLITTLE, California ROD GRAMS, Minnesota TOM CAMPBELL, California SAM BROWNBACK, Kansas JOSEPH R. PITTS, Pennsylvania JEFF SESSIONS, Alabama PAUL RYAN, Wisconsin CHARLES S. ROBB, Virginia PETE STARK, California PAUL S. SARBANES, Maryland CAROLYN B. MALONEY, New York EDWARD M. KENNEDY, Massachusetts DAVID MINGE, Minnesota JEFF BINGAMAN, New Mexico MELVIN L. WATT, North Carolina SHELLEY S. HYMES, Executive Director JAMES D. GWARTNEY, Chief Economist HOWARD ROSEN, Minority Staff Director (ii) CONTENTS OPENING STATEMENTS OF MEMBERS Senator Connie Mack, Chairman ........ ..................... I Representative Pete Stark, Ranking Minority Member ..... ...... 4 Senator Bill Frist . ......................................... 6 Senator Edward M. Kennedy ............................... 31 Senator Robert F. Bennett .. .............................. 33 Representative David Minge ................................ 36 Senator Jeff Sessions .............. ....................... 39 WITNESSES PANELI Statement of Carolyn Boyer-Fortier, Breast Cancer Survivor. ...... 8 Statement of Dr. Steven Shak, Staff Scientist and Senior Director of Medical Affairs, Genentech ........................... 11 Statement of Joan London, Rheumatoid Arthritis Patient .... ..... 13 Statement of Dr. Robert Bunning, Director of the Arthritis Program at National Rehabilitation Hospital.
    [Show full text]
  • 1 VITA ROBERT HINRICHS BATES Office Address
    VITA ROBERT HINRICHS BATES Office Address: Department of Government 1737 Cambridge Street Harvard University Cambridge, Massachusetts 02138 Telephone: (617) 496-0919/5-9889 EDUCATION B.A., Haverford College, 1964 Ph.D., Massachusetts Institute of Technology, 1969 AWARDS AND FELLOWSHIPS Haverford College: Phi Beta Kappa, Summa Cum Laude, Kurzman Prize in Political Science, Founder's Club. John Simon Guggenheim Memorial Foundation, 1985-86. John M. Olin, Visiting Research Professor, Graduate School of Business, Stanford University, January-July 1991. Carnegie Corporation, Carnegie Scholar, 2001-2002. Riker Prize for Political Science, 2000 Moore Distinguished Scholar, Caltech, 2004. Russell Sage Foundation, Senior Scholar 2008-2009 Phillips Lecturer, Haverford College, 1992; 50th Anniversary, Distinguished Lecturer, Institute for Social Research, University of Michigan, 1999; Patten Lecture, University of Indiana, 2000; Inaugural Ralph Bunche Lecture, UCLA, 2001. FIELD EXPERIENCE 1968-69: fifteen months research in the urban communities of the copper belt in Zambia, studying the political party and the mineworker's union 1971-72: fourteen months research in the rural areas of Zambia, studying the politics and economics of rural development programs in village communities 1977: four weeks consultancy in the Sudan 1978: two months research in West and Eastern Africa 1981: three months in Uganda and Kenya 1982: six weeks research in Uganda 1983-84: six months research in Kenya 1988: four weeks research in Zambia 1989: eight weeks research
    [Show full text]
  • How Scientist/Founders Lead Successful
    HOW SCIENTIST/FOUNDERS LEAD SUCCESSFUL BIOPHARMACEUTICAL ORGANIZATIONS: A STUDY OF THREE COMPANIES Lynn Johnson Langer A DISSERTATION Submitted to the Ph.D. in Leadership & Change Program of Antioch University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May, 2008 This is to certify that the dissertation entitled: HOW SCIENTIST/FOUNDERS LEAD SUCCESSFUL BIOPHARMACEUTICAL ORGANIZATIONS: A STUDY OF THREE COMPANIES prepared by Lynn Johnson Langer is approved in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Leadership & Change. Approved by: ______________________________________________________________________ Alan E. Guskin, Ph.D., Chair date ______________________________________________________________________ Jon Wergin, Ph.D., Committee Member date ______________________________________________________________________ Mitch Kusy, Ph.D., Committee Member date ______________________________________________________________________ Alice Sapienza, DBA, External Reader date Copyright 2008 Lynn Johnson Langer All rights reserved Acknowledgements I arrive at this place in my journey to becoming a scholar supported in love and friendship by so many people. I must thank first and foremost my husband, Eric Langer, who has supported me in many ways, but particularly with my education. I thank my daughter, Julia Annemarie, my study partner. We shout across the hall to each other, complaining and laughing about all the work. I thank her for her support and the opportunity to be a role model. She never once complained about the plays and events I missed because I was away at a residency. I thank my son, Adam and his wife, Megan who through their lives, remind me to follow my dreams. I thank my son, Benjamin, who shows me that through hard work, we can accomplish great things.
    [Show full text]
  • Conference Day One Thursday, April 23Rd 2015 – Main Conference Room
    Conference Day One Thursday, April 23rd 2015 – Main Conference Room 8.55 Chairperson’s Opening Remarks Hans Schikan, Former Chief Executive Officer, Prosensa 9.00 Keynote: Data driving diagnostics - Clinically relevant information from ordinary photos, and an algorithm to aid in diagnoses of rare diseases Christoffer Nellaker, Research Fellow, Medical Research Foundation’s Functional Genomics Unit, Oxford University 9.30 Keynote: Is the market sustainable? Henri Termeer, Former Chairman, President and CEO, Genzyme (on video) 10.00 Speed Networking & Networking coffee break 11.00 Good medicine is good business: Transforming lives and meeting unmet needs Stephanie Okey, Senior Vice President and Head of North America, Genetic Diseases and US General Manager, Genzyme 11.20 The Great Debate: “The Price is Too Damn High!”…or is it? FOR: The orphan population is so small the rest of the population can more than cover the cost Ram Selvaraju, Managing Director, Equity Research – Healthcare, MLV & Co. AGAINST: First there was rare, now there’s ultra-rare. And it seems every other disease is rare and every other drug orphan. WE won’t be able to afford it – period. Ed Pazalla, VP, National Medical Director for Pharmacy Policy and Strategy, Aetna 12.00 Networking Lunch 1:00 Lunch session: Pediatric vouchers to expedite rare disease treatments in children Gayatri Rao, Director, Office of Orphan Product Development, FDA 1.30 2 x 40-minute roundtables with a 10 minute break in-between. Please sign up in the exhibition hall lounge. 1: How does miscommunication
    [Show full text]
  • Influence | Intuition
    invivo.pharmaintelligence.informa.com MAY 2019 Invol. 37 ❚ no. 05 Vivopharma intelligence ❚ informa LEADERSHIPInnovation | Influence | Intuition Biotech CEOs: Can Scientist Founders Beyond The Watershed: Gene Therapy The Eye Travels Wide: ProQR’s Bid Remain In Charge? Investment And Promise For Leadership In Genetics Of Sight PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | May 2019 THE LEADERSHIP ISSUE 10 16 22 Biotech CEOs: Can Scientist- Beyond The Watershed: Rentschler Biopharma: Founders Remain In Charge? Gene Therapy Investment Growing And Innovating As MELANIE SENIOR And Promise A CDMO Business Founder-CEOs do not typically remain at JO SHORTHOUSE LUCIE ELLIS the helm as biotechs mature. Exceptions Janet Lambert, CEO of the Alliance for Frank Mathias, CEO of Rentschler to that rule are multiplying, though, Regenerative Medicine, recently spoke to Biopharma, a contract development especially in Europe as companies aim In Vivo about the tremendous levels of and manufacturing organization, talks directly for Nasdaq. investment the cell and gene therapy to In Vivo about the company’s new industries are attracting, as well as corporate strategy and why he allowed 18 26 reasons why Europe excels at incubating months to prepare that plan for delivery. advanced product development. TISSIUM CEO’s Vision Is To Make 36 The Tissue Recon Label Stick 30 ASHLEY YEO Leading In Product Develop- The Eye Travels Wide: ment Means Planning
    [Show full text]
  • Breakout Sessions and Panelists Bios
    Healthcare Startups for the Tech Savvy 10:45 AM – 11:45 AM, Ferman Conference Room Finding opportunities in the healthcare arena MODERATOR Edward Chwieseni, President and CEO, PracticeForces Edward Chwieseni is the Director of IT for Moffitt Cancer Center and its wholly owned subsidiary M2Gen. He is responsible for IT strategy, planning and implementation efforts at Moffitt and M2Gen, including software development, data warehousing, project management, clinical trials systems, research IT projects and IT infrastructure and has over 28 years of experience working in IT. Before joining the Moffitt group, Mr. Chwieseni held multiple senior (CIO, CTO, and CTIO) positions at a number of early stage companies. Mr. Chwieseni has a BS (Hons) Computer Science from Teesside, an MBA from Phoenix, and is currently working on his PhD. PANELISTS Pranam Ben, Founder & CEO, The Garage @PranamBen / @TheGarageIn Pranam is a successful healthcare, tech entrepreneur. His most recent venture, Visions@work was acquired in 2011 by a publicly traded, global IT corporation NIIT Technologies. He has experience conducting business internationally a result of managing operations in the UK, Japan, India and the UAE. Ben has been featured in CBS Money Watch, Marketwatch, Fast Company, business.com, Silicon India Magazine, Florida Trend, Orlando Business Journal and the Orlando Sentinel, among other media outlets. In 2014, Ben was honored in the inaugural Orlando Business Journal CEO of the Year class, for his leadership, ability to navigate market conditions, and lasting impact in the community. Under Ben’s leadership, The Garage received recognition as one of Orlando Business Journal’s “Best Places to Work” in 2014 for offering an outstanding work environment with great perks.
    [Show full text]